Trials / Active Not Recruiting
Active Not RecruitingNCT04925973
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (the TRIUMPH Study)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib 10 MG [Xeljanz] | Tofacitinib 10mg PO BID |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2021-06-14
- Last updated
- 2023-10-24
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04925973. Inclusion in this directory is not an endorsement.